Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment
| Autor: | Brian Perrochet, Naoko A Ronquest, Walter Ling, Chinmay Deshpande, David Farabee, Christian Heidbreder, Vijay R Nadipelli, Susan M Learned, Caitlyn T. Solem |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
050101 languages & linguistics
medicine.medical_specialty 010504 meteorology & atmospheric sciences Psychometrics business.industry Intraclass correlation 05 social sciences Discriminant validity 01 natural sciences Clinical trial Quality of life Cronbach's alpha Cohort Physical therapy Medicine 0501 psychology and cognitive sciences business 0105 earth and related environmental sciences Buprenorphine medicine.drug |
| Zdroj: | Substance Abuse and Rehabilitation. 10:13-21 |
| ISSN: | 1179-8467 |
| DOI: | 10.2147/sar.s198361 |
| Popis: | Purpose: The Treatment Effectiveness Assessment (TEA) is a patient-centered instrument for evaluating treatment progress and recovery from substance use disorders, including opioid use disorder (OUD). We assessed the TEA's reliability and validity and determined minimal clinically important differences (MIDs) in participants with moderate to severe OUD. Patients and methods: The TEA measures change in four single-item domains (substance use, health, lifestyle, community involvement) from treatment initiation across the duration of a treatment program. Self-reported responses range from 1 ("none or not much") to 10 ("much better") with items summed to a total score ranging from 4-40. We assessed floor and ceiling effects, internal consistency, test-retest reliability, known-groups validity (ANOVA stratified by current health status [36-Item Short Form Health Survey item 1]), convergent/divergent validity, and MIDs using data from a phase 3, open-label clinical trial of buprenorphine extended-release monthly injection for subcutaneous use (BUP-XR). Participants with OUD completed the TEA at screening and before monthly injections for up to 12 months. Results: Among 410 participants (mean age 38 years; 64% male), the mean baseline (pre-injection 1) TEA total score was 25.4 (SD 9.7), with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|